Table 4.

Safety data of three randomized controlled studies of olmesartan alone or in combination with a calcium channel blocker vs. an angiotensin converting enzyme inhibitor alone or in combination with a calcium channel blocker

(Reproduced from [40, 41, 44] with permission)

Elderly hypertensive patients [40]	Olmesartan 10–40 mg (n = 712)	Ramipril 2.5–10 mg (n = 714)	p value
Any AE	105 (14.7)	96 (13.4)	0.480
Drug-related AE	21 (2.9)	23 (3.2)	0.767
Discontinuation due to AE	21 (2.9)	16 (2.2)	0.400

Adult hypertensive patients [41]	Olmesartan 40 mg + amlodipine 10 mg (n = 244)	Perindopril 8 mg + amlodipine 10 mg (n = 241)	p value
Any AE	125 (51.2)	114 (47.3)	0.387
Drug-related AE	61 (25.0)	62 (25.7)	0.854
Discontinuation due to AE	18 (7.4)	19 (7.9)	0.834

Hypertensive patients with type 2 diabetes mellitus [44]	Olmesartan 20–40 mg + amlodipine 5–10 mg (n = 128)	Perindopril 4-8 mg + amlodipine 5–10 mg (n = 132)	p value
Any AE	32 (25.0)	37 (28.0)	0.580
Drug-related AE	10 (7.8)	13 (9.8)	0.563
Discontinuation due to AE	4 (3.1)	2 (1.5)	0.387

AE adverse event